CITATION REPORT List of articles citing

Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19)

DOI: 10.5582/bst.2020.03072 BioScience Trends, 2020, 14, 156-158.

Source: https://exaly.com/paper-pdf/77663488/citation-report.pdf

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|----|---|----------------|-----------|
| 37 | Hydroxychloroquine in Hospitalized Patients with COVID-19: Real-World Experience Assessing Mortality. <i>Pharmacotherapy</i> , 2020 , 40, 1072-1081 | 5.8 | 9 |
| 36 | Inhibiting fusion with cellular membrane system: therapeutic options to prevent severe acute respiratory syndrome coronavirus-2 infection. <i>American Journal of Physiology - Cell Physiology</i> , 2020 , 319, C500-C509 | 5.4 | 4 |
| 35 | Synergistic association of clioquinol with antifungal drugs against biofilm forms of clinical Fusarium isolates. <i>Mycoses</i> , 2020 , 63, 1069-1082 | 5.2 | 3 |
| 34 | Known drugs and small molecules in the battle for COVID-19 treatment. <i>Genes and Diseases</i> , 2020 , 7, 528-534 | 6.6 | 9 |
| 33 | Chloroquine and hydroxychloroquine - safety profile of potential COVID-19 drugs from the rheumatologist perspective. <i>Annals of Agricultural and Environmental Medicine</i> , 2021 , 28, 122-126 | 1.4 | O |
| 32 | The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status. <i>Journal of Infection and Public Health</i> , 2020 , 13, 1601-1610 | 7.4 | 60 |
| 31 | The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial. <i>BMC Infectious Diseases</i> , 2020 , 20, 78 | 6 ⁴ | 61 |
| 30 | Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives. <i>Acta Pharmacologica Sinica</i> , 2020 , 41, 1377-1386 | 8 | 11 |
| 29 | Hydroxychloroquine in COVID-19: The Study Points to Premature Decisions on Efficacy While Bells Ringing for Safety. <i>Clinical Pharmacology: Advances and Applications</i> , 2020 , 12, 115-121 | 1.5 | 1 |
| 28 | Otologic and Audiologic Considerations for COVID-19. <i>Otolaryngology - Head and Neck Surgery</i> , 2020 , 163, 110-111 | 5.5 | 11 |
| 27 | The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19. <i>Cytokine and Growth Factor Reviews</i> , 2020 , 54, 51-62 | 17.9 | 50 |
| 26 | Can early treatment of patients with risk factors contribute to managing the COVID-19 pandemic?. <i>Journal of Global Health</i> , 2020 , 10, 010377 | 4.3 | 9 |
| 25 | Conjunctivitis as a Sentinel of SARS-CoV-2 Infection: a Need of Revision for Mild Symptoms. <i>SN Comprehensive Clinical Medicine</i> , 2020 , 2, 1-6 | 2.7 | 5 |
| 24 | The care of patients with Duchenne, Becker, and other muscular dystrophies in the COVID-19 pandemic. <i>Muscle and Nerve</i> , 2020 , 62, 41-45 | 3.4 | 37 |
| 23 | Antivirals for COVID-19: A critical review. <i>Clinical Epidemiology and Global Health</i> , 2021 , 9, 90-98 | 1.8 | 79 |
| 22 | Is optical coherence tomography angiography a useful tool in the screening of hydroxychloroquine retinopathy?. <i>International Ophthalmology</i> , 2021 , 41, 27-33 | 2.2 | 5 |
| 21 | COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases. <i>Rheumatology International</i> , 2021 , 41, 257-273 | 3.6 | O |

| 20 | Consensus Statement on the Management of Duchenne Muscular Dystrophy in Saudi Arabia During the Coronavirus Disease 2019 Pandemic. <i>Frontiers in Pediatrics</i> , 2021 , 9, 629549 | 3.4 | 4 |
|----|---|------|----|
| 19 | Multidrug treatment for COVID-19. <i>Drug Discoveries and Therapeutics</i> , 2021 , 15, 39-41 | 5 | 5 |
| 18 | Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021 , 35, 101658 | 5.3 | 2 |
| 17 | What Every Diabetologist Should Know about SARS-CoV-2: State of Knowledge at the Beginning of 2021. <i>Journal of Clinical Medicine</i> , 2021 , 10, | 5.1 | 3 |
| 16 | Quercetin Phytosome as a potential candidate for managing COVID-19. <i>Minerva Gastroenterology</i> , 2021 , 67, | 3 | 5 |
| 15 | Brief review on repurposed drugs and vaccines for possible treatment of COVID-19. <i>European Journal of Pharmacology</i> , 2021 , 898, 173977 | 5.3 | 14 |
| 14 | A call to caution when hydroxychloroquine is given to elderly patients with COVID-19. <i>International Journal of Infectious Diseases</i> , 2021 , 106, 265-268 | 10.5 | 0 |
| 13 | The Challenges and Successes of Dealing with the COVID-19 Pandemic in India. <i>Research and Reports in Tropical Medicine</i> , 2021 , 12, 205-218 | 2.9 | O |
| 12 | Emerging Potential of Metallodrugs to Target Coronavirus: Efficacy, Toxicity and their Mechanism of Action. <i>Asian Journal of Chemistry</i> , 2021 , 33, 1191-1207 | 0.4 | 0 |
| 11 | Safety and Efficacy of Chloroquine/Hydroxychloroquine in SARS-CoV-2 Infection. <i>Asian Journal of Chemistry</i> , 2021 , 33, 1718-1722 | 0.4 | 1 |
| 10 | The journey of antimalarial drugs against SARS-CoV-2: Review article. <i>Informatics in Medicine Unlocked</i> , 2021 , 24, 100604 | 5.3 | 17 |
| 9 | Repurposing old drugs as antiviral agents for coronaviruses. <i>Biomedical Journal</i> , 2020 , 43, 368-374 | 7.1 | 29 |
| 8 | Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multinational network cohort study. <i>Rheumatology</i> , 2021 , 60, 3222-3234 | 3.9 | 10 |
| 7 | Risk of depression, suicidal ideation, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multi-national network cohort study. | | О |
| 6 | Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil. <i>Advances in Rheumatology</i> , 2021 , 61, 60 | 3 | 4 |
| 5 | Novel antiviral effects of chloroquine, hydroxychloroquine, and green tea catechins against SARS-CoV-2 main protease and 3C-like protease for COVID-19 treatment <i>Clinical Nutrition Open Science</i> , 2022 , | | 3 |
| 4 | Clinical update on COVID-19 for the emergency and critical care clinician: Medical management <i>American Journal of Emergency Medicine</i> , 2022 , 56, 158-170 | 2.9 | 2 |
| 3 | The Potential of Nanobodies for COVID-19 Diagnostics and Therapeutics. | | Ο |

Dual action anti-inflammatory/antiviral isoquinoline alkaloids as potent naturally occurring anti-SARS-CoV -2 agents: A combined pharmacological and medicinal chemistry perspective.

О

Exploring the Link Between Malaria and COVID-19. 2023, 311-338

Ο